Call Start: 11:00 January 1, 0000 11:57 AM ET ProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2022 Earnings Conference Call May 13, 2022, 11:00 AM ET Company Participants Ted Karkus – Chairman & Chief Executive Officer Conference Call Participants Yi Chen – H.C. Wainwright & Co. Robert Titus – MRT Industries Dennis Waldman – Barrett Productions Kyle Krueger – Apollo Capital Fred McDonald – Private Investor Operator Good day and welcome to the ProPhase Labs First Quarter 2022. Financial Results and Corporate Update Con ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 000-21617 ProPhase Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2577138 (State or other ju ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2021 Earnings Conference Call March 29, 2022 11:00 AM ET Company Participants Ted Karkus - Chairman & CEO Conference Call Participants Yi Chen - H.C. Wainwright Dennis Waldman - Barrett Productions Lee Harper - Hammock Patrick Patterson - Private Investor Robert Donaher - Private Investor Fred McDonald - Private Investor Operator Good morning, everyone, and welcome to the ProPhase Labs Fourth Quarter 2021 Financial Results and Corporate Update Conference Call. All partic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact name of registrant as specified in its charter) WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission file number 000-21617 ProPhase Labs, Inc. Delaware 23-2577138 (State or other jurisdi ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q3 2021 Earnings Conference Call November 12, 2021 11:00 AM ET Company Participants Jules Abraham – Investor Relations CORE IR Ted Karkus – Chairman and Chief Executive Officer Conference Call Participants Patrick Patterson – Private Investor Fred MacDonald – Private Investor George Gianakos – Private Investor Operator Welcome to the ProPhase Labs Third Quarter 2021 Financial Results and Corporate Update Conference Call. All participants will be in listen-only mode. [Operat ...

ProPhase 1 NASDAQ: PRPH Corporate Presentation September 2021 Forward Looking Statements This presentation contains forward‐looking statements relating to our strategy and business objectives. All statements other than statements of historical facts included in this presentation may be deemed to be forward‐looking statements including statements related to our plans to grow our new whole genome sequencing (WGS) business by leveraging our existing CLIA labs and retail relationships and to build a genomics da ...

1 ProPhase NASDAQ: PRPH Corporate Presentation August 2021 Forward Looking Statements This presentation contains forward‐looking statements relating to our strategy and business objectives. All statements other than statements of historical facts included in this presentation may be deemed to be forward‐looking statements including statements related to our plans to grow our new whole genome sequencing (WGS) business by leveraging our existing CLIA labs and retail relationships and to build a genomics datab ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q2 2021 Earnings Conference Call August 13, 2021 11:00 AM ET Company Participants Jules Abraham – Investor Relations-CORE IR Ted Karkus – Chairman and Chief Executive Officer Conference Call Participants Patrick Patterson – Private Investor Fred MacDonald – Private Investor Dennis Waldman – Private Investor George Jane Kens – Private Investor Operator Good day and welcome to the ProPhase Labs’ Second Quarter 2021 Financial Results and Corporate Update Conference Call. All ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission file number 000-21617 ProPhase Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2577138 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission file number 000-21617 ProPhase Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdic ...